poisar

Stocks · News reference

Veradermics’ VDPHL01 Phase 2 Trial Met Key Endpoints In Female Pattern Hair Loss, Showing Rapid Onset Of Hair Growth, 88.9%–90.0% Patient‑Reported Improvement At Month 6; Topline Phase 2/3 Study 306 Results Expected In H1 2027

Benzinga Newsdesk

VDPHL01, a novel orally-administered extended-release minoxidil formulation, achieved fast onset of hair growth with the majority of study participants reporting improvement in hair coverage as early as Month 2 and

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

MANE
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Benzinga Newsdesk

    Veradermics Q2 EPS $(0.58) Beats $(0.65) Estimate

    Veradermics (NYSE:MANE) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.65) by 10.77 percent. This is a 97.6 percent increase over losses of $(24.19) per share from the

    MANE
  2. SEC EDGAR

    8-K filing — Veradermics, Inc (MANE)

    Filed: 2026-08-11 AccNo: 0001827635-26-000028 Size: 641 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

    MANE